Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study
Abstract Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications. This study examined the outcomes of administering febuxostat to persons...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-04-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43162-025-00446-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172454514720768 |
|---|---|
| author | Showkat Azad Pradip Kumar Dutta Md Nurul Huda Mohammad Abdul Kader Biplob Kumar Barua Mohammad Shawkat Ali Maria Mehjabin Akhi Mishu Rahman Jannatul Efte Ekra Md. Sujan Islam Sadia Afrin Mohammed Mehadi Hassan Chowdhury Subodh Kumar Sarkar Ashekul Islam |
| author_facet | Showkat Azad Pradip Kumar Dutta Md Nurul Huda Mohammad Abdul Kader Biplob Kumar Barua Mohammad Shawkat Ali Maria Mehjabin Akhi Mishu Rahman Jannatul Efte Ekra Md. Sujan Islam Sadia Afrin Mohammed Mehadi Hassan Chowdhury Subodh Kumar Sarkar Ashekul Islam |
| author_sort | Showkat Azad |
| collection | DOAJ |
| description | Abstract Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications. This study examined the outcomes of administering febuxostat to persons diagnosed with asymptomatic hyperuricemia in CKD (stages 3 and 4). Methods A single-patient blinded; placebo-controlled study was carried out at Chittagong Medical College Hospital in Chattogram 4203 over a 1-year period. Participants were randomly assigned to two groups: one group received a daily dose of 40 mg of febuxostat while the other was given placebo tablets. As necessary, diuretics, antihypertensives, and antidiabetics were administered. Evaluations, which included patient history, physical examinations, outcomes, and pertinent tests, were performed at baseline, the 3rd month, and the 6th month. Results There were 105 similar-baseline patients in each group. The mean serum uric acid (SUA) level in the febuxostat group lowered from 8.55 to 4.92 mg/dL after 6 months, while in the placebo control it elevated from 8.10 to 8.99. In febuxostat group, the mean eGFR elevated from 25.28 to 27.01 ml/min/1.73 m2, while in the placebo control it reduced from 26.81 to 23.32. In the febuxostat group, at the 6-month mark, eGFR differed across groups following a substantial decrease in systolic and diastolic blood pressure (P < 0.05). Conclusions In our clinical setting, febuxostat proved more effective than a placebo in reducing serum uric acid levels and maintaining eGFR in patients with stage 3 and 4 CKD. Hence, febuxostat could be employed to treat hyperuricemia-associated asymptomatic chronic renal disease. |
| format | Article |
| id | doaj-art-da46480dcd814676be1a4040e9443c97 |
| institution | OA Journals |
| issn | 2090-9098 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj-art-da46480dcd814676be1a4040e9443c972025-08-20T02:20:05ZengSpringerOpenThe Egyptian Journal of Internal Medicine2090-90982025-04-013711810.1186/s43162-025-00446-5Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional studyShowkat Azad0Pradip Kumar Dutta1Md Nurul Huda2Mohammad Abdul Kader3Biplob Kumar Barua4Mohammad Shawkat Ali5Maria Mehjabin Akhi6Mishu Rahman7Jannatul Efte Ekra8Md. Sujan Islam9Sadia Afrin10Mohammed Mehadi Hassan Chowdhury11Subodh Kumar Sarkar12Ashekul Islam13Imperial Hospital,Marine City Medical College HospitalChittagong Medical College HospitalChittagong Medical College HospitalChittagong Medical College HospitalChittagong Metropolitan HospitalMawlana Bhashani Science and Technology UniversityMawlana Bhashani Science and Technology UniversityMawlana Bhashani Science and Technology UniversityMawlana Bhashani Science and Technology UniversityMawlana Bhashani Science and Technology UniversityNoakhali Science and Technology UniversityNoakhali Science and Technology UniversityMawlana Bhashani Science and Technology UniversityAbstract Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications. This study examined the outcomes of administering febuxostat to persons diagnosed with asymptomatic hyperuricemia in CKD (stages 3 and 4). Methods A single-patient blinded; placebo-controlled study was carried out at Chittagong Medical College Hospital in Chattogram 4203 over a 1-year period. Participants were randomly assigned to two groups: one group received a daily dose of 40 mg of febuxostat while the other was given placebo tablets. As necessary, diuretics, antihypertensives, and antidiabetics were administered. Evaluations, which included patient history, physical examinations, outcomes, and pertinent tests, were performed at baseline, the 3rd month, and the 6th month. Results There were 105 similar-baseline patients in each group. The mean serum uric acid (SUA) level in the febuxostat group lowered from 8.55 to 4.92 mg/dL after 6 months, while in the placebo control it elevated from 8.10 to 8.99. In febuxostat group, the mean eGFR elevated from 25.28 to 27.01 ml/min/1.73 m2, while in the placebo control it reduced from 26.81 to 23.32. In the febuxostat group, at the 6-month mark, eGFR differed across groups following a substantial decrease in systolic and diastolic blood pressure (P < 0.05). Conclusions In our clinical setting, febuxostat proved more effective than a placebo in reducing serum uric acid levels and maintaining eGFR in patients with stage 3 and 4 CKD. Hence, febuxostat could be employed to treat hyperuricemia-associated asymptomatic chronic renal disease.https://doi.org/10.1186/s43162-025-00446-5Asymptomatic hyperuricemiaCKDEGFRFebuxostatSerum uric acid |
| spellingShingle | Showkat Azad Pradip Kumar Dutta Md Nurul Huda Mohammad Abdul Kader Biplob Kumar Barua Mohammad Shawkat Ali Maria Mehjabin Akhi Mishu Rahman Jannatul Efte Ekra Md. Sujan Islam Sadia Afrin Mohammed Mehadi Hassan Chowdhury Subodh Kumar Sarkar Ashekul Islam Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study The Egyptian Journal of Internal Medicine Asymptomatic hyperuricemia CKD EGFR Febuxostat Serum uric acid |
| title | Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study |
| title_full | Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study |
| title_fullStr | Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study |
| title_full_unstemmed | Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study |
| title_short | Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study |
| title_sort | febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia an interventional study |
| topic | Asymptomatic hyperuricemia CKD EGFR Febuxostat Serum uric acid |
| url | https://doi.org/10.1186/s43162-025-00446-5 |
| work_keys_str_mv | AT showkatazad febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT pradipkumardutta febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mdnurulhuda febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mohammadabdulkader febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT biplobkumarbarua febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mohammadshawkatali febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mariamehjabinakhi febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mishurahman febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT jannatulefteekra febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mdsujanislam febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT sadiaafrin febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT mohammedmehadihassanchowdhury febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT subodhkumarsarkar febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy AT ashekulislam febuxostatefficientlyreducestheprogressionofchronickidneydiseaseinasymptomatichyperuricemiaaninterventionalstudy |